黑色素瘤的临床肿瘤浸润淋巴细胞经验：过去、现在、未来。
The Clinical TIL Experience in Melanoma: Past, Present, Future.
作者信息
Smithy James W, Schoenfeld Adam J, Betof Warner Allison
机构信息
Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
出版信息
Transplant Cell Ther. 2025 Mar;31(3S):S626-S634. doi: 10.1016/j.jtct.2024.11.013.
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability.
2024年2月，美国食品药品监督管理局最近批准了利菲鲁赛尔（lifileucel），这是30多年来对不可切除黑色素瘤采用肿瘤浸润淋巴细胞（TIL）进行过继性细胞治疗研究的成果。在本综述中，我们重点介绍黑色素瘤TIL疗法的关键历史数据，以及为提高其疗效和适用性而正在进行的努力。
Zotero 插件